Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 4 6Phase NA 3Phase 3 3Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Dutasteride × Clear all
NCT00780754 2018-03-06

Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia

Kaunas University of Medicine

Phase 3 Completed
200 enrolled
Genitourinary

Prostatic Neoplasms

NCT00056407 2016-09-23

REDUCE

GlaxoSmithKline

Phase 3 Completed
8,231 enrolled 34 charts
Genitourinary

Prostatic Neoplasms

NCT00398281 2014-01-10

Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer

National Cancer Institute (NCI)

Phase 3 Completed
450 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡